Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.

Akira SaitoJoji KitayamaHisanaga HorieKoji KoinumaRie KawashimaHideyuki OhzawaHironori YamaguchiHiroshi KawahiraToshiki MimuraAlan Kawarai LeforNaohiro Sata

Published in: Cancer research communications (2021)

DPP-4i has been shown to enhance the antitumor effects of immunotherapy. However, we found that DPP-4i significantly impairs the outcomes of patients with colorectal cancer who underwent curative resection, possibly through acceleration of EMT and creation of a tumor-permissive immune microenvironment. This suggests that DPP-4i must be used with caution until its safety is fully confirmed by further studies of the mechanistic effects on existing cancers in humans.

Keyphrases

prognostic factors
end stage renal disease
ejection fraction
newly diagnosed
stem cells
epithelial mesenchymal transition
patient reported outcomes
signaling pathway